Kronos Bio
KRON
KRON was delisted on the 20th of June, 2025.
80 hedge funds and large institutions have $54.3M invested in Kronos Bio in 2023 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 15 increasing their positions, 26 reducing their positions, and 23 closing their positions.
15% more capital invested
Capital invested by funds: $47.3M → $54.3M (+$6.99M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
1.4% less ownership
Funds ownership: 56.21% → 54.82% (-1.4%)
8% less funds holding
Funds holding: 87 → 80 (-7)
30% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 23
42% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$4.47M |
| 2 |
PCIG
Partners Capital Investment Group
Boston,
Massachusetts
|
+$1.81M |
| 3 |
Mariner
Overland Park,
Kansas
|
+$1.45M |
| 4 |
AI
Acuitas Investments
Seattle,
Washington
|
+$522K |
| 5 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$500K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$4.25M |
| 2 |
BlackRock
New York
|
-$2.77M |
| 3 |
State Street
Boston,
Massachusetts
|
-$954K |
| 4 |
Morgan Stanley
New York
|
-$662K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$587K |
KRON Hedge Fund Activity: Q2 2023 in Review
80 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Kronos Bio (KRON) for Q2 2023, worth a combined $54.3M — up 15% from $47.3M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of KRON and 16 opened new positions — a net loss of 7 holders — while 26 trimmed existing stakes and 15 added.
The largest buyer was BVF Inc, opening a new position worth an estimated $4.47M. The largest seller was JP Morgan Chase, cutting an estimated $4.25M.
- 80 institutional investors held Kronos Bio (KRON) as of Q2 2023, down from 87 in Q1 2023.
- Funds reported $54.3M of Kronos Bio stock for Q2 2023, up 15% quarter-over-quarter.
- 16 funds opened new Kronos Bio positions in Q2 2023 and 23 closed out, a net change of -7 holders.
- The largest Kronos Bio buyer in Q2 2023 was BVF Inc, an estimated $4.47M added.
- The largest Kronos Bio seller in Q2 2023 was JP Morgan Chase, an estimated $4.25M sold.
Based on aggregated 13F filings for Q2 2023.